Trial · NCT03085797
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period (TP) (52 Weeks) | STARTED | Placebo | 201 | |
| Treatment Period (TP) (52 Weeks) | STARTED | Mepolizumab 100 mg SC | 206 | |
| Treatment Period (TP) (52 Weeks) | Completed Investigational Product (IP) | Placebo | 167 | |
| Treatment Period (TP) (52 Weeks) | Completed Investigational Product (IP) | Mepolizumab 100 mg SC | 183 | |
| Treatment Period (TP) (52 Weeks) | Not Completed IP | Placebo | 34 | |
| Treatment Period (TP) (52 Weeks) | Not Completed IP | Mepolizumab 100 mg SC | 23 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Adverse Event | Placebo | 4 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Adverse Event | Mepolizumab 100 mg SC | 4 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Lack of Efficacy | Placebo | 11 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Lack of Efficacy | Mepolizumab 100 mg SC | 5 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Protocol Deviation | Placebo | 1 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Protocol Deviation | Mepolizumab 100 mg SC | 0 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Stopping Criteria | Placebo | 1 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Stopping Criteria | Mepolizumab 100 mg SC | 1 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Physician Decision | Placebo | 2 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Physician Decision | Mepolizumab 100 mg SC | 1 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Withdrawal by Par. | Placebo | 15 | |
| Treatment Period (TP) (52 Weeks) | Withdrew IP Due to: Withdrawal by Par. | Mepolizumab 100 mg SC | 12 | |
| Treatment Period (TP) (52 Weeks) | COMPLETED | Placebo | 184 | |
| Treatment Period (TP) (52 Weeks) | COMPLETED | Mepolizumab 100 mg SC | 189 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03085797/flow